## Risk Stratification & Disease Classification This patient has **low-risk prostate cancer** by all major criteria: ### Low-Risk Disease Criteria (NCCN/EAU) | Criterion | Patient's Value | Status | |-----------|-----------------|--------| | **Gleason score** | 6 (3+3) | ✓ Low-risk | | **PSA** | 8.5 ng/mL | ✓ <10 ng/mL | | **Clinical stage** | T1c (PSA-detected) | ✓ Localized | | **Tumor burden** | 1/12 cores, <50% | ✓ Minimal | | **PSA density** | 0.08 ng/mL/mL | ✓ <0.15 | | **Life expectancy** | >15 years | ✓ Sufficient | **Key Point:** All five parameters indicate **low-risk, indolent disease**. ### Active Surveillance vs. Definitive Treatment **Active Surveillance (AS)** is now the **standard of care** for low-risk prostate cancer because: 1. **Natural history:** Gleason 6 disease has extremely low metastatic potential (~0.5% at 15 years) 2. **Overtreatment avoidance:** ~50% of men with low-risk cancer never progress and would be unnecessarily harmed by surgery/radiation 3. **Quality of life:** Avoids incontinence, erectile dysfunction, and bowel toxicity in men who may never need treatment 4. **Equivalent oncologic outcomes:** Survival curves for AS vs. immediate treatment are nearly identical in low-risk cohorts 5. **Reclassification risk:** ~25–30% show higher-grade disease on repeat biopsy, triggering intervention ### Active Surveillance Protocol **Mnemonic: PSAR** - **PSA** monitoring: every 3–6 months initially, then annually - **Serum PSA doubling time (PSADT):** >3 years is favorable; <1 year triggers biopsy - **Annual DRE** - **Repeat biopsy:** at 1–2 years, then every 2–3 years (or if PSA rises rapidly) **Clinical Pearl:** Reclassification to intermediate/high-risk on repeat biopsy occurs in ~25–30% of AS patients and mandates treatment. This is why surveillance is not "doing nothing" — it is **active monitoring with treatment thresholds**. ### Why Other Options Are Inappropriate **Radical prostatectomy:** - Causes incontinence in 5–15% and erectile dysfunction in 20–40% - Unnecessary in low-risk disease with excellent prognosis - Overtreatment in a disease that may never progress **EBRT:** - Causes rectal toxicity (bleeding, diarrhea) in 10–15% - Erectile dysfunction in 30–50% - Unjustified in low-risk, potentially indolent disease **ADT monotherapy:** - Causes hot flushes, metabolic syndrome, bone loss, cardiovascular events - No role in low-risk localized disease - Reserved for metastatic or unfit patients **High-Yield:** **Gleason 6 + PSA <10 + T1–T2 + minimal burden = Active Surveillance**, not surgery or radiation. This is the **most frequently tested scenario** in NEET PG. **Warning:** Do not confuse **active surveillance** (planned monitoring with treatment triggers) with **watchful waiting** (symptomatic treatment only, no curative intent). AS is appropriate for fit men with low-risk disease; watchful waiting is for unfit/limited life expectancy. [cite:Harrison 21e Ch 97; NCCN Prostate Cancer Guidelines 2023]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.